MARKET

CLLS

CLLS

Cellectis
NASDAQ
2.170
-0.040
-1.81%
Opening 11:25 12/07 EST
OPEN
2.190
PREV CLOSE
2.210
HIGH
2.200
LOW
2.170
VOLUME
34.68K
TURNOVER
48.14K
52 WEEK HIGH
9.57
52 WEEK LOW
2.000
MARKET CAP
98.76M
P/E (TTM)
-0.9466
1D
5D
1M
3M
1Y
5Y
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a liv...
GlobeNewswire · 5d ago
Cellectis Granted U.S. Patent #11498971 BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy
Benzinga · 11/15 11:15
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced...
GlobeNewswire · 11/10 14:05
Cellectis Publishes Manuscript In Frontiers Bioengineering And Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN And TALE Base Editors
Benzinga · 11/10 07:52
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights10/31/2...
GlobeNewswire · 11/08 21:30
Cellectis Business Update; Preclinical Data On Talen-Edited Smart Car T-Cells To Be Presented At SITC 2022; ASH 2022 Sponsored Programs UCART123 Abstract Selected For Oral Presentation & Preclinical Data On UCARTCS1 Selected For Poster Presentation
Benzinga · 11/03 21:39
Cellectis Q3 Adj. EPS $(0.58) Misses $(0.45) Estimate, Sales $1.92M Miss $13.43M Estimate
Benzinga · 11/03 20:42
Cellectis GAAP EPS of -$0.63 misses by $0.14, revenue of $1.92M
Seekingalpha · 11/03 20:41
More
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers kinds of Cellectis SA (ADR) stock information, including NASDAQ:CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.